Literature DB >> 7509764

Influence of inflammation and atrophy on pancreatic secretory trypsin inhibitor levels within the gastric mucosa.

R J Playford1, A M Hanby, C Quinn, J Calam.   

Abstract

BACKGROUND/AIMS: Gastrointestinal epithelia contain a powerful protease inhibitor called pancreatic secretory trypsin inhibitor (PSTI). Gastric mucus obtained from patients with atrophic gastritis or gastric ulceration shows changes suggestive of excessive proteolytic digestion. Therefore, the aim of this study was to examine whether mucosal PSTI levels are affected by gastritis and/or ulceration.
METHODS: Mucosal PSTI levels were measured in 12 patients with normal gastric histology and 26 patients with gastritis and/or gastric ulceration.
RESULTS: In control subjects, mean gastric PSTI concentrations were 990 ng/mg protein (95% confidence interval, 819-1195) in the antrum and 445 ng/mg protein (95% confidence interval, 395-502) in the body. Immunostaining for PSTI was strongly positive in the pyloric glands of the antrum and in the foveolar/surface and mucus neck cells of the gastric body. Tissue levels of PSTI were reduced by 40% in biopsy specimens showing superficial gastritis (P = 0.035) and by 75% in biopsy specimens showing atrophic gastritis and/or gastric ulceration (P < 0.001). Immunostaining was also reduced in specimens showing atrophic gastritis.
CONCLUSIONS: The decrease in tissue PSTI levels associated with gastric atrophy probably represents a permanent reduction in one of the mucosal defense mechanisms. This may lead to the maintenance and even expansion of the gastritic process with time.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7509764     DOI: 10.1016/0016-5085(94)90709-9

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  8 in total

1.  Distribution and expression of pancreatic secretory trypsin inhibitor and its possible role in epithelial restitution.

Authors:  T Marchbank; R Chinery; A M Hanby; R Poulsom; G Elia; R J Playford
Journal:  Am J Pathol       Date:  1996-03       Impact factor: 4.307

Review 2.  Peptides and gastrointestinal mucosal integrity.

Authors:  R J Playford
Journal:  Gut       Date:  1995-11       Impact factor: 23.059

3.  Human pancreatic secretory trypsin inhibitor stabilizes intestinal mucosa against noxious agents.

Authors:  Tania Marchbank; Asif Mahmood; Anthony J Fitzgerald; Jan Domin; Matt Butler; Robert A Goodlad; George Elia; Helen M Cox; David A van Heel; Subrata Ghosh; Raymond J Playford
Journal:  Am J Pathol       Date:  2007-11       Impact factor: 4.307

4.  Expression pattern of serine protease inhibitor kazal type 3 (Spink3) during mouse embryonic development.

Authors:  Jun Wang; Masaki Ohmuraya; Masahiko Hirota; Hideo Baba; Gang Zhao; Motohiro Takeya; Kimi Araki; Ken-ichi Yamamura
Journal:  Histochem Cell Biol       Date:  2008-04-02       Impact factor: 4.304

5.  Identification of genes up-regulated in urothelial tumors: the 67-kd laminin receptor and tumor-associated trypsin inhibitor.

Authors:  Christine P Diggle; Sheena Cruickshank; Jonathon D Olsburgh; Stephanie Pellegrin; Barbara Smith; Rosamonde E Banks; Peter J Selby; Margaret A Knowles; Jennifer Southgate; Patricia Harnden
Journal:  Am J Pathol       Date:  2003-08       Impact factor: 4.307

6.  Influence of inflammatory bowel disease on the distribution and concentration of pancreatic secretory trypsin inhibitor within the colon.

Authors:  R J Playford; A M Hanby; K Patel; J Calam
Journal:  Am J Pathol       Date:  1995-02       Impact factor: 4.307

7.  Liver Cancer-Specific Serine Protease Inhibitor Kazal Is a Potentially Novel Biomarker for the Early Detection of Hepatocellular Carcinoma.

Authors:  Felix Lu; Pir Ahmad Shah; Abhishek Rao; Cynthia Gifford-Hollingsworth; Anne Chen; Gary Trey; Mina Soryal; Arslan Talat; Aysha Aslam; Bilal Nasir; Saad Choudhry; Rizwan Ishtiaq; Hanna Sanoff; Lanla F Conteh; Anne Noonan; Ke-Qin Hu; Carl Schmidt; Min Fu; Jesse Civan; Gary Xiao; Daryl T-Y Lau; Xuanyong Lu
Journal:  Clin Transl Gastroenterol       Date:  2020-12       Impact factor: 4.396

8.  SPINK1 promotes colorectal cancer progression by downregulating Metallothioneins expression.

Authors:  R Tiwari; S K Pandey; S Goel; V Bhatia; S Shukla; X Jing; S M Dhanasekaran; B Ateeq
Journal:  Oncogenesis       Date:  2015-08-10       Impact factor: 7.485

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.